As of September 30, 2026, TransMedics Group, Inc. carries a market capitalization of 2.53B, placing it among publicly traded companies globally. Its enterprise value stands at 2.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.53B |
| Enterprise Value | 2.86B |
TransMedics Group, Inc.'s next confirmed earnings release is scheduled for March 2, 2027.
| Earnings Date | 3/2/2027 |
As of September 30, 2026, TransMedics Group, Inc. has 34.72M shares outstanding.
| Shares Outstanding | 34.72M |
As of September 30, 2026, TransMedics Group, Inc. trades at a trailing price-to-earnings ratio of 19.69. The price-to-sales ratio is 3.91, and the price-to-book ratio stands at 5.20.
| PE Ratio | 19.69 |
| PS Ratio | 3.91 |
| PB Ratio | 5.20 |
| P/TBV Ratio | 5.41 |
| P/FCF Ratio | 73.25 |
| P/OCF Ratio | 25.32 |
As of September 30, 2026, TransMedics Group, Inc. trades at an EV/EBITDA multiple of 25.54 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 37.48 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.86B versus a market cap of 2.53B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 4.45 |
| EV / EBITDA | 25.54 |
| EV / EBIT | 37.48 |
As of September 30, 2026, TransMedics Group, Inc. maintains a current ratio of 4.53, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 157.41, indicating elevated leverage, while an interest coverage ratio of 5.07 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 4.53 |
| Quick Ratio | 3.98 |
| Debt / Equity | 157.41 |
| Debt / EBITDA | 6.83 |
| Interest Coverage | 5.07 |
Over the twelve months ended September 30, 2026, TransMedics Group, Inc. posted a return on equity (ROE) of 31.89, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 11.73, measuring how efficiently the asset base is converted into earnings. The company generates approximately 714,928.28 in revenue per employee across its workforce of 898.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.86 indicates how many times TransMedics Group, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 31.89 |
| Return on Assets (ROA) | 11.73 |
| Revenue Per Employee | 714,928.28 |
| Employee Count | 898.00 |
| Inventory Turnover | 5.86 |
Over the twelve months ended September 30, 2026, TransMedics Group, Inc. recorded an income tax benefit of -62.49M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 64.96M, leaving 127.45M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | -62.49M |
These figures are as of the close on November 17, 2026.
| 50-Day Moving Average | 71.41 |
Over the twelve months ended September 30, 2026, TransMedics Group, Inc. generated 642.01M in revenue and converted that into 127.45M in net income, yielding earnings per share of 3.21. EBITDA reached 111.93M, while operating income came in at 76.27M.
| Revenue | 642.01M |
| Gross Profit | 376.24M |
| Operating Income | 76.27M |
| Pretax Income | 64.96M |
| Net Income | 127.45M |
| EBITDA | 111.93M |
| EBIT | 76.27M |
| Earnings Per Share (EPS) | 3.21 |
As of September 30, 2026, TransMedics Group, Inc. holds 434.94M in cash and equivalents against 764.87M in total debt, resulting in a net debt position of 14.87M. Total book value stands at 485.89M, with working capital of 476.09M providing operational flexibility.
| Cash & Cash Equivalents | 434.94M |
| Total Debt | 764.87M |
| Net Debt | 14.87M |
| Equity (Book Value) | 485.89M |
| Book Value Per Share | 13.99 |
| Working Capital | 476.09M |
TransMedics Group, Inc. produced 99.13M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -59.70M in capital expenditures, free cash flow totaled 39.44M - equivalent to 1.14 per share.
| Operating Cash Flow | 99.13M |
| Capital Expenditures | -59.70M |
| Free Cash Flow | 39.44M |
| FCF Per Share | 1.14 |
Over the twelve months ended September 30, 2026, TransMedics Group, Inc. posted a gross margin of 58.60, reflecting its pricing power and cost economics. The operating margin of 11.88 and net profit margin of 19.85 provide insight into operational efficiency.
| Gross Margin | 58.60 |
| Operating Margin | 11.88 |
| Pretax Margin | 10.12 |
| Profit Margin | 19.85 |
| EBITDA Margin | 17.43 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 1.37, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.21, meaning TransMedics Group, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -0.21 |
| FCF Yield | 1.37 |
As of September 30, 2026, TransMedics Group, Inc. has an Altman Z-Score of 2.66, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.66 |